Structural Interpretation, Spectral Analysis, and Structure Confirmation

Definitive structure confirmation of a synthesised compound integrates evidence from every spectroscopic and spectrometric technique described in this phase...

Definitive structure confirmation of a synthesised compound integrates evidence from every spectroscopic and spectrometric technique described in this phase into a single, internally consistent structural conclusion, rather than relying on any individual technique in isolation. The standard integrated interpretation workflow begins with mass spectrometry (typically HRMS) to establish the molecular formula; proceeds through FTIR to confirm the presence of expected functional groups and the absence of unexpected ones (such as a residual starting-material functional group indicating incomplete reaction); and concludes with complete one- and two-dimensional NMR analysis to establish the full atom-by-atom connectivity and, where relevant, stereochemistry of the molecule. A structure is considered definitively confirmed only when every piece of spectroscopic evidence — molecular formula, functional group pattern, and complete NMR connectivity — is mutually consistent with a single proposed structure and inconsistent with any plausible alternative isomeric structure; any unresolved discrepancy between techniques must be actively investigated and resolved, rather than selectively disregarded, before a structure is reported with confidence.

Advanced Concepts: Cryo-EM and Structural Biology Integration

While the techniques described in this phase characterise the small-molecule compound itself, complementary structural biology techniques — X-ray crystallography of a ligand–target co-crystal, and increasingly cryo-electron microscopy for large or membrane-embedded targets historically resistant to crystallisation — directly visualise how the synthesised and characterised compound engages its biological target, closing the loop between the computational design described in Phase 1 and the biological activity data generated later in the discovery pipeline. The growing accessibility of cryo-EM, driven by advances in detector technology and computational image processing, has substantially expanded the range of pharmaceutically important targets, including GPCRs and ion channels in defined conformational states, for which high-resolution structural data can now inform structure-based medicinal chemistry design.

Frequently Asked Questions

Why is HRMS considered a stronger structural proof than standard (low-resolution) mass spectrometry? Standard mass spectrometry confirms only the nominal (integer) molecular weight, which can be shared by multiple distinct molecular formulae; HRMS measures mass with sufficient precision to distinguish between these formulae directly, providing considerably stronger evidence for a specific proposed structure.

Is NMR alone ever sufficient to confirm a novel compound's structure without mass spectrometric data? No — regulatory and publication standards consistently require independent molecular formula confirmation by mass spectrometry alongside NMR connectivity data, since NMR alone cannot rule out certain isomeric possibilities that share an identical connectivity pattern but differ in molecular formula, such as compounds differing by a water or halogen substitution.

Common Interview and Viva Questions

• Explain why DEPT is able to distinguish CH, CH2, and CH3 carbons but not quaternary carbons.
• What structural information does HMBC provide that HSQC cannot, and why?
• Why is electrospray ionisation described as a 'soft' ionisation technique?
• Differentiate nominal mass from exact mass and explain the significance of this distinction for HRMS.
• Why is GC-MS preferred over LC-MS for residual solvent analysis?
• Describe the standard integrated workflow used to confirm the structure of a newly synthesised compound.

Common Mistakes and Troubleshooting

A common interpretive error is assigning a tentative NMR structure based on chemical shift and multiplicity alone without cross-referencing two-dimensional connectivity data, risking a plausible but ultimately incorrect structural assignment, particularly for compounds bearing multiple similar substituents. Broad, poorly resolved NMR signals are most often attributable to sample impurity, residual paramagnetic contamination, or the use of an inappropriate deuterated solvent for the compound's solubility profile, and are best resolved by re-purifying the sample and confirming solvent choice before questioning the underlying chemical structure. Where a mass spectrum fails to show a clear molecular ion peak, acquiring the spectrum under both positive- and negative-ion electrospray conditions, or supplementing with an alternative ionisation technique such as atmospheric pressure chemical ionisation, will frequently resolve the ambiguity.